Concepedia

Scott M. Wasserman

SM

Statistics

Publications

87

Citations

18.6K

H-Index

57

Active since

1977

Affiliations

Amgen (United States)(Current)

Brigham and Women's Hospital

Thrombolysis in Myocardial Infarction Study Group

Louisville Metabolic and Atherosclerosis Research Center

Oslo University Hospital

Scott M. Wasserman is an author at Amgen (United States) specializing in medicine, atherosclerosis, and cardiovascular disease.

ORCID

Top concepts

Publications per year

1977–2020

87

Publications

87

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

Marc S. Sabatine, Robert P. Giugliano, Stephen D. Wiviott et al. · New England Journal of Medicine · 2015 · 1.5K citations · Full text

, , +19

Romosozumab in Postmenopausal Women with Low Bone Mineral Density

Michael R. McClung, Andreas Grauer, Steven Boonen et al. · New England Journal of Medicine · 2014 · 1.2K citations

Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients

Stephen J. Nicholls, Rishi Puri, Todd J. Anderson et al. · JAMA · 2016 · 1.1K citations · Full text

Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk

Michelle L. O’Donoghue, Sergio Fazio, Robert P. Giugliano et al. · Circulation · 2019 · 895 citations · Full text

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

Frederick J. Raal, Evan A. Stein, Robert Dufour et al. · The Lancet · 2014 · 734 citations

, , +11

1–5 of 87